Target intelligence / Profile preview

Fast skeletal muscle myosin-2 (SkMII)

Target
SkMII
Molecular classification
Motor protein, ATPase, Enzyme, Cytoskeletal protein
01

Overview

Fast skeletal muscle myosin-2 is a specialized motor protein found in type II muscle fibers, responsible for rapid force generation and high-velocity contraction (UniProt, PMC4916140). It functions as an ATPase, utilizing energy from ATP to drive the sliding of actin filaments within the sarcomere (PubMed 11784865). This protein is a critical therapeutic target in muscular dystrophies, such as Duchenne and Becker muscular dystrophy, where reducing the mechanical stress of contraction can prevent fiber damage and slow disease progression (Edgewise Therapeutics, PMC8544410). Small molecule inhibitors like sevasemten (EDG-5506) selectively target this isoform to stabilize the sarcomere without affecting cardiac or slow-twitch muscle function (PMC8544410). Additionally, research into myosin modulators extends to conditions involving muscle hypercontractility and spasticity, highlighting its central role in neuromuscular health and disease (MotorPharma, PNAS 113.47).

Other names
Fast skeletal myosinFast-twitch skeletal muscle myosin IIType II myosinSkeletal muscle myosin IIMYH1MYH2MYH4
02

Mechanism of action

Selective allosteric inhibition of the fast skeletal muscle myosin II ATPase activity, which stabilizes the myosin-ADP-Pi complex in a weak actin-binding state, thereby reducing force production and mechanical stress on the sarcomere.

03

Biological functions

Muscle contractionATP hydrolysisForce generationGliding motility
04

Disease associations

Duchenne muscular dystrophyBecker muscular dystrophySpasticityMuscle hypercontractilitySarcopenia
05

Safety considerations

Excessive muscle weaknessReduced peak exercise capacityPotential off-target inhibition of cardiac or smooth muscle myosinMuscle fatigue
06

Interacting drugs

Sevasemten (EDG-5506)

4 more in the full profile.

07

Biomarkers

Serum creatine kinase (CK)North Star Ambulatory Assessment (NSAA)6-minute walk test (6MWT)Grip strength

Beyond the preview

Go deeper on Fast skeletal muscle myosin-2 (SkMII).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fast skeletal muscle myosin-2 (SkMII).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call